10th Jun 2008 07:00
Embargoed Release: 07:00hrs Tuesday 10 June 2008
Nanoscience Inc.
('Nanoscience' or the 'Group')
MyAmego™ First Commercial Contract Win
Nanoscience, the specialist niche investor in emerging technologies with strong commercial propositions for the healthcare and electronic sectors, is pleased to announce that Sentinel Healthcare Solutions Limited ('Sentinel'), where the Group is the largest shareholder with a 50 per cent interest, has received its first commercial contract from a local authority for its recently launched MyAmego™ product to be installed in a new purpose built care home in Scotland.
Sentinel is currently installing its MyAmego™ system into the local authority mixed disability (including dementia) 25-bedroom care home, due to open in late June. The MyAmego™ system will go 'live' from July 1 and Sentinel is also providing training for the use of the system. The local authority care home provider, which currently operates eight care homes in Scotland, with two further homes under construction, chose MyAmego™ for its proven ability to monitor resident's mobility and manage patient risk. MyAmego™ is fully compliant with the 'telecare' requirements of the Mental Capacity Act laid down by the UK Government.
MyAmego™, which was launched on 29 April at the Naidex Conference in Birmingham, is a ground-breaking, patent-pending, cost effective assistive telecare technology system. It enables care home operators specialising in the care of people with dementia and other disabilities to deliver a better quality of care through rigorous risk management procedures and also to construct personalised detailed assessments which directly relate to the individual.
Sentinel's MyAmego™ uses the Sentinel:Monitor platform to monitor dementia residents with an electronic device such as a bracelet or necklace, and captures data via wireless monitors placed around the care home in a mesh network. The service intelligently analyses the user's environment in relation to the user's needs and automatically alerts carers for assistance when needed in addition to facilitating the adjustment of care plans through analysis reports of the user's activities. The privacy of the personal care and monitoring profile is decided by and managed with the individual protecting the independence of the person by the personalisation of the individuals care plan which further allows carers and family to have quality, detailed and direct feedback on all aspects to the persons care.
MyAmego™ has successfully completed trials covering a number of conditions in both private care homes and local authorities across the UK. The market size for registered dementia sufferers in the UK alone exceeds 750,000, with similar ratios to population in all developed countries.
The Directors of Nanoscience are also pleased to report that Sentinel is in final discussions with potential distributors in Spain to licence MyAmego™ in their country and other Spanish-speaking geographies.
Guy Spelman, chief executive officer of Nanoscience, commented:
'We are very impressed that Sentinel has managed to win a contract with a prominent local authority in Scotland so soon after launching its MyAmego™ product and we hope the successful installation of MyAmego™ into the new dementia purpose built care home will translate into the rollout of the product in the rest of the local authority's care homes as well as the adoption of MyAmego™ by other local authorities in the near future.'
-Ends-
Further Information:
Guy Spelman
Nanoscience Inc.
07767 338 967
Vikki Krause
Hansard Group
020 7245 1100
Related Shares:
FST.L